EUVIMEDPoznaj EUVIMED
BeobachtungsstudieOpen access · CC BY 4.0

Affinity Proteomics‐Based Non‐Invasive Detection of Clinically Significant Liver Disease

Sriram Balasubramani, Katharina Remih, Anna Sophie Karl, Julia Alexandra Borchert, Christina Schrader, Malin Fromme iD, Can Kayatekin, Bailin Zhang, Mikhail Levit, Pavithra Krishnaswami, Louise E van Eekeren, Leo A B Joosten and 3 more

Alimentary Pharmacology & Therapeutics · 2026-07 · 64 (1) · 74-88

DOI: 10.1111/apt.70656 ↗

At a glance

Beobachtungsstudie in Alimentary Pharmacology & Therapeutics, published online on 2026-04-16. Written by Sriram Balasubramani and 14 co-authors. Institution: Medical Clinic III, Gastroenterology, Metabolic Diseases and Intensive Care, Health Care Provider of the European Reference Network on Rare Liver Dis…. Major MEDLINE topics: Liver Diseases, Proteomics. Cited 2 times so far (Crossref); 63 references. The full text is freely available (open access, CC BY 4.0). Funded by: European Association for the Study of the Liver, CSL Behring, Arrowhead Pharmaceuticals.

AbstraktSubjectsDane bibliograficzneCiteRelated studies

Abstract (original language)

Background

Non‐invasive biomarkers predicting major adverse liver outcomes (MALO) are urgently needed.

Aims

We assessed a novel, proximity extension assay‐based high‐throughput targeted proteomics.

Methods

Plasma proteomic data (> 2900 proteins) and clinical information were accessed from the population‐based UK Biobank cohort, comprising ~52,000 individuals with a median follow‐up of > 10 years, including obese (~12,700) and diabetic (~1500) participants. Validation cohorts comprised 287 participants with severe alpha1‐antitrypsin deficiency (Pi*ZZ genotype), and 960 people living with HIV, who underwent liver stiffness measurement (LSM) via transient elastography. Selected proteomic parameters were compared to routine measurements. Bayes‐moderated linear models (covariates: age and sex) assessed the differential abundance. Logistic regression was used to develop and validate a prognostic score.

Results

Routine gamma‐glutamyltransferase (GGT) and aspartate aminotransferase (AST) strongly correlated with proteomic measurements ( r = 0.92 and r = 0.71, respectively). Similarly, proteomic‐based thrombospondin‐2 levels correlated with immunoassay‐based values ( r = 0.85). Twenty proteins were consistently associated with future MALOs/increased liver stiffness in all cohorts. A novel five‐component proteomic score derived from the UK Biobank cohort demonstrated superior predictive power for MALOs (AUROC = 0.84) compared to AST‐to‐platelet‐ratio index (AUROC = 0.73) and Fibrosis‐4 index (AUROC = 0.72), with stable performance in obese and diabetic subcohorts. In people living with HIV and alpha1‐antitrypsin deficiency patients, all five components increased across fibrosis stages and the proteomic score outperformed AST‐to‐platelet‐ratio/Fibrosis‐4 index in predicting significant LSM‐based liver fibrosis.

Conclusions

We identify a new proteomic score comprising epithelial/hepatic stellate cell markers that yields a robust predictive performance across different liver disease aetiologies. Thereby, we demonstrate the usefulness of emerging proteomic techniques in hepatology. Trial Registration The registry study is listed at ClinicalTrials.gov (NCT02929940)

Subjects

MeSH terms (MEDLINE)

Liver DiseasesProteomicsAdultFemaleHumansMaleMiddle Agedalpha 1-Antitrypsin DeficiencyAspartate AminotransferasesBiomarkersCohort StudiesElasticity Imaging Techniquesgamma-GlutamyltransferaseUnited Kingdom

Author keywords

PEAUK Biobankalpha‐1 antitrypsin deficiencynon‐invasive liver testplasma proteomics

Substances

Aspartate AminotransferasesBiomarkersgamma-Glutamyltransferase

Authors and institutions

  • Medical Clinic III, Gastroenterology, Metabolic Diseases and Intensive Care, Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN RARE LIVER), University Hospital RWTH Aachen, Aachen, Germ…
  • Department of Gastroenterology and Hepatology, Medical University Lausitz-Carl-Thiem, Cottbus, Germany.
  • Sanofi, Cambridge, Massachusetts, USA.
  • Department of Internal Medicine, Radboud University Medical Centre, Nijmegen, the Netherlands.
  • Department of Medical Genetics, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
  • Prague University of Economics and Business, Prague, Czech Republic.

ORCID profiles: Malin Fromme

Funding

  • European Association for the Study of the Liver
  • CSL Behring
  • Arrowhead Pharmaceuticals
  • German Liver Foundation

Cite

APA

Balasubramani, S., Remih, K., Karl, A. S., Borchert, J. A., Schrader, C., Fromme, M., Kayatekin, C., Zhang, B., Levit, M., Krishnaswami, P., van Eekeren, L. E., Joosten, L. A. B., Otten, T., Tomanová, P., & Strnad, P. (2026). Affinity Proteomics‐Based Non‐Invasive Detection of Clinically Significant Liver Disease. Alimentary Pharmacology & Therapeutics, 64(1), 74-88. https://doi.org/10.1111/apt.70656

Vancouver

Balasubramani S, Remih K, Karl AS, Borchert JA, Schrader C, Fromme M, et al. Affinity Proteomics‐Based Non‐Invasive Detection of Clinically Significant Liver Disease. Alimentary Pharmacology & Therapeutics. 2026;64(1):74-88. doi:10.1111/apt.70656

BibTeX
@article{Balasubramani2026,
  author = {Balasubramani, Sriram and Remih, Katharina and Karl, Anna Sophie and Borchert, Julia Alexandra and Schrader, Christina and Fromme, Malin and Kayatekin, Can and Zhang, Bailin and Levit, Mikhail and Krishnaswami, Pavithra and van Eekeren, Louise E and Joosten, Leo A B and Otten, Twan and Tomanová, Petra and Strnad, Pavel},
  title = {Affinity Proteomics‐Based Non‐Invasive Detection of Clinically Significant Liver Disease},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  volume = {64},
  number = {1},
  pages = {74--88},
  doi = {10.1111/apt.70656}
}
Start for free →